MedTrace Logo

A Study to Assess the Safety, Pharmacokinetics and Effectiveness of AGS-16C3F Monotherapy in Subjects With Renal Cell Carcinoma (RCC) of Clear Cell or Papillary Histology

NCT01672775 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2024-11-01

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and pharmacokinetics and assess the immunogenicity and effectiveness of AGS-16C3F in subjects with renal cell cancer (RCC).

Conditions

  • Carcinoma, Renal Cell
  • Renal Cell Carcinoma of Papillary Histology
  • Renal Cell Carcinoma With Clear Cell Histology
  • Renal Cell Carcinoma With Non-Clear Cell Histology

Interventions

DRUG

AGS-16C3F

intravenous (IV) infusion

Sponsors & Collaborators

  • Agensys, Inc.

    lead INDUSTRY

Principal Investigators

  • Medical Director · Agensys, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-18
Primary Completion
2017-02-21
Completion
2017-02-21

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01672775 on ClinicalTrials.gov